以下文章来源于e公司 ，作者证券时报 吴志 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 A股逐步迎来业绩预告高峰。截至1月20日晚间，已有超过500家A股公司披露2025年业绩预告或业绩快报。 百余家公司预计净利翻倍 据证券时报记者统计，截至1月20日19时，共有525家A股公司披露2025年业绩预告或业绩快报，其中约200家企业预计2025年业绩实现增长，逾百 家企业预计归母净利润最高增幅将超过100%。 | | | 部分预告2025年净利润高增长的A股公司 | | | | --- | --- | --- | --- | --- | | 证券代码 | 证券简称 | 预告净利润上限 (亿元) | 预告净利润同比 增长上限(%) | 业绩预告 类型 | | 300871.SZ | 回盛生物 | 2.71 | 1444.54 | 扭亏 | | 003035.SZ | 南网能源 | 3.60 | 719.35 | 扭亏 ...

（原标题：百余家A股公司，去年净利或翻倍！） A股逐步迎来业绩预告高峰。截至1月20日晚间，已有超过500家A股公司披露2025年业绩预告或业绩快 报。 2025年，在AI技术的强势赋能下，科技领域多个细分赛道保持高景气态势，产业链上下游大量企业凭 借技术迭代与需求释放，实现了业绩的稳健增长。而光伏、白酒、生猪养殖等细分领域受市场环境波 动、供需格局调整等因素影响，企业业绩承压。 百余家公司预计净利翻倍 | | | 部分预告2025年净利润高增长的A股公司 | | | | --- | --- | --- | --- | --- | | 证券代码 | 证券简称 | 预告净利润上限 | 预告净利润同比 | 业绩预告 | | | | (亿元) | 增长上限(%) | និគ្គភិ | | 300871.SZ | 回盛生物 | 2.71 | 1444.54 | 拥亏 | | 003035.SZ | 南网能源 | 3.60 | 719.35 | 扭亏 | | 300435.SZ | 中泰股份 | 4.80 | 715.70 | 扭亏 | | 600104.SH | 上汽集团 | 110.00 | 558.00 | 预 ...

A股逐步迎来业绩预告高峰。截至1月20日晚间，已有超过500家A股公司披露2025年业绩预告或业绩快 报。 2025年，在AI技术的强势赋能下，科技领域多个细分赛道保持高景气态势，产业链上下游大量企业凭 借技术迭代与需求释放，实现了业绩的稳健增长。而光伏、白酒、生猪养殖等细分领域受市场环境波 动、供需格局调整等因素影响，企业业绩承压。 百余家公司预计净利翻倍 据证券时报记者统计，截至1月20日19时，共有525家A股公司披露2025年业绩预告或业绩快报，其中约 200家企业预计2025年业绩实现增长，逾百家企业预计归母净利润最高增幅将超过100%。 目前预计净利润增幅最高的是回盛生物。该公司主要从事兽用药品、饲料及添加剂研发、产销。1月9 日，公司披露业绩预告，预计2025年归母净利润2.35亿元至2.71亿元，同比增长1265.93%至1444.54%。 回盛生物表示，2025年公司积极开拓海内外市场，营业收入实现国内、国外双增长。收入的增长促进了 净利润同比大幅增长，同时公司技术创新升级、制剂与原料药产能利用率提升及原料药价格上涨等因素 驱动盈利能力提升。 良好的业绩推动回盛生物股价大幅攀升。自业绩预告披 ...

Core Insights - As of January 12, 2026, 106 A-share listed companies have released their 2025 earnings forecasts, with nearly 60% indicating positive expectations, including 60 companies expecting profit increases or recoveries, while 40 companies forecast declines or losses [1] Group 1: Positive Earnings Forecasts - The main sectors with positive earnings forecasts include pharmaceuticals, semiconductors, computers, communications, and other electronic equipment manufacturing, primarily concentrated in the ChiNext and STAR Market [1] - Companies in the non-ferrous metal mining and chemical manufacturing sectors also reported positive forecasts, influenced by rising prices of non-ferrous metals and chemical products [1] Group 2: Notable Company Performances - Huisheng Bio is expected to turn a profit in 2025, with a projected net profit of 235 million to 271 million yuan, representing a year-on-year increase of 1265.93% to 1444.54% [3] - The profit increase for Huisheng Bio is attributed to market expansion, improved production capacity, and a reduction in financial costs due to early redemption of convertible bonds [3][4] - Wanfu Bio, however, is projected to report a net loss of 46 million to 69 million yuan in 2025, marking its worst performance since its listing in 2015, with a significant decline in net profit and a first-time loss in non-recurring net profit [5][8] Group 3: Industry Challenges - Wanfu Bio's challenges stem from domestic market price reductions, changes in product structure, and increased financial burdens due to reduced capitalization of interest expenses [6][8] - The real estate sector, particularly companies like Greenland Holdings, continues to face significant challenges, with projected net losses of 16 billion to 19 billion yuan due to declining asset prices and extended project development cycles [6]

Group 1 - The core point of the article is that Jinhe Biological has announced the pledge of shares by its controlling shareholder, Jinhe Holdings, which does not pose any risk to the company's operations or governance [1] - As of the announcement date, Jinhe Holdings has pledged a total of 85.32 million shares, accounting for 38.92% of its holdings, while the total pledged shares by Jinhe Holdings and its concerted parties account for 33.3% of their holdings [1] - Jinhe Biological's revenue composition for the first half of 2025 is as follows: veterinary chemical drugs 61.83%, agricultural product processing 19.76%, veterinary biological products 11.12%, environmental protection business 4.97%, and others 2.15% [1] Group 2 - The current market capitalization of Jinhe Biological is 5.2 billion yuan [1] - The article also highlights the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated $80 billion [1]

Group 1 - The core point of the article is that Jinhe Biological has announced a stock issuance plan to raise up to 300 million yuan for various projects, including wastewater treatment and product storage [1] - The stock issuance will be directed towards no more than 35 specific investors, with the pricing set at no less than 80% of the average stock price over the previous 20 trading days [1] - The total investment for the wastewater treatment expansion and water resource recycling project is approximately 158 million yuan, with about 136 million yuan expected to be funded from the raised capital [1] Group 2 - Jinhe Biological's revenue composition for the first half of 2025 includes: veterinary chemical drugs at 61.83%, agricultural product processing at 19.76%, veterinary biological products at 11.12%, environmental protection business at 4.97%, and others at 2.15% [1] - As of the report date, Jinhe Biological has a market capitalization of 5.4 billion yuan [2]